AAMI heads into the week having given back nearly 3.5% on a share price that has nonetheless outrun analyst targets — with the Chief Legal Officer's $6.7m sale in early May now sitting as the most tangible market signal of the past fortnight.
The insider angle is the clearest story here. Richard Hart, AAMI's Chief Legal Officer, sold a combined 100,000 shares across two tranches on May 4 at an average of roughly $67, raising around $6.7 million. That's a meaningful disposal — the largest recent transaction by a senior officer — and it came with the stock trading near its highs for the year. The mid-May director equity awards to Barbara Trebbi, Robert Chersi, and Chairman John Paulson carry no cash value and read as routine compensation rather than a directional signal. The net 90-day insider position, once those award shares are included, shows a technical net-positive of 110,000 shares, but strip out the zero-value awards and the cash flow from insiders has been firmly in the sell column.
Short positioning is not the story here. At 2.1% of free float, bears have barely engaged. The borrow pool is vast — availability runs at nearly 9,000% of current short interest, meaning there is no scarcity in the lending market and no squeeze dynamics in play. Cost to borrow at 0.48% is near its lowest level of the past month and far too cheap to suggest any active pressure. Short interest nudged up 5% on the week to around 758,000 shares, but that move is noise, not a trend. The ORTEX short score of 32.7 confirms this: it's a middling reading, consistent with a stock that short sellers regard as broadly fairly priced.
Analyst consensus tells a mildly cautious story. All three firms covering the stock — RBC Capital, Evercore ISI, and Morgan Stanley — hold neutral-equivalent ratings (Sector Perform, In-Line, Equal-Weight respectively). Notably, both Evercore and RBC lifted targets in late April and early May following what appears to be a strong earnings print. Evercore raised its target from $60 to $70 on May 4; RBC went to $66. Morgan Stanley moved to $60 in late April. Against a current price of $68.11, those targets sit 2–8% below where the stock is trading — meaning the Street, in aggregate, has been chasing the stock higher while simultaneously refusing to recommend it. The mean consensus target of $63.33 implies around 7% downside. Valuation multiples offer limited comfort: the P/E of 13.4x has drifted lower over 30 days while the P/B of 7.3x has risen, reflecting a market re-rating the asset base rather than earnings power.
Ownership is stable but concentrated. Paulson & Co. holds 21.7% — a dominant, anchored position that structurally limits the float and helps explain why short interest remains so thin. BlackRock and Vanguard hold a further 19% combined, though both reported modest additions in recent quarters. Jennison Associates lifted its stake by 113,000 shares as of March 31, while Woodline Partners added 143,000 and Two Sigma built 195,000 — a cluster of active managers adding exposure. On the other side, Empyrean trimmed 96,000 shares and Soros Fund cut 89,000. Net institutional flow looks modestly constructive, but the Paulson overhang remains the structural feature.
Peer context sharpens the picture. IVZ dropped 6.7% on the week and CG fell 5.6%, with BX giving back 3.5%. AAMI's 3.4% decline was broadly in line with the asset manager peer group, suggesting this week's move is sector beta rather than a stock-specific event. The next earnings event is confirmed for June 11 — the prior two prints produced modest positive one-day moves of 1.1% and 0.6%, with five-day drifts of 4.9% and 2.2% respectively, suggesting the market has rewarded AAMI's results without dramatic reactions.
The June 11 print arrives with the stock trading above every analyst's target, an active seller on record in the C-suite, and a peer group under broad pressure — making price action around that date worth watching closely.
See the live data behind this article on ORTEX.
Open AAMI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
